Exclusive Summary

• This product, as an FDA-certified generic drug, is already registered in the US and its API conforms to USP standards, ensuring globally recognized quality and high trustworthiness.
• Celecoxib is widely used worldwide for chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis, indicating a huge and stable market demand.
• The product is frequently recommended as a first or second-line treatment in guidelines, possessing clear clinical value and market potential, especially for patients requiring long-term medication.
• Compared to the innovator drug, this generic offers significant cost advantages, meeting the cost-control needs of both developing and developed countries, thereby enhancing market competitiveness.
• The flexible distribution cooperation model facilitates rapid market expansion beyond the United States.